|
First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans
|
12/22/22
|
First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans
|
PDF
|
|
Bausch Health Wins DUOBRII® and BRYHALI® Patent Infringement Case
|
12/02/22
|
Bausch Health Wins DUOBRII® and BRYHALI® Patent Infringement Case
|
PDF
|
|
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
|
12/01/22
|
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
|
PDF
|
|
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Covenants
|
11/29/22
|
Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Covenants
|
PDF
|
|
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
|
11/04/22
|
Salix Will Present Rifaximin Data at AASLD's The Liver Meeting(R) 2022
|
PDF
|
|
Bausch Health Companies Inc. Announces Third-Quarter 2022 Results
|
11/03/22
|
Bausch Health Companies Inc. Announces Third-Quarter 2022 Results
|
pdf
|
|
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
|
11/01/22
|
Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
|
PDF
|
|
Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge
|
10/31/22
|
Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge
|
PDF
|
|
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
|
10/24/22
|
Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting
|
PDF
|
|
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
|
10/20/22
|
Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference
|
PDF
|
|
Bausch Health to Announce Third Quarter 2022 Results on Nov. 3
|
10/13/22
|
Bausch Health to Announce Third Quarter 2022 Results on Nov. 3
|
pdf
|
|
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population
|
10/12/22
|
Salix Pharmaceuticals Releases Liver Health Annual Trends Report Underscoring Challenges in Caring for Growing Chronic Liver Disease and Cirrhotic Patient Population
|
PDF
|
|
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022
|
10/05/22
|
Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022
|
pdf
|
|
Salix Pharmaceuticals Applauds Implementation of K76.82 – a New ICD-10 Code for Hepatic Encephalopathy
|
10/03/22
|
Salix Pharmaceuticals Applauds Implementation of K76.82 – a New ICD-10 Code for Hepatic Encephalopathy
|
pdf
|
|
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations
|
09/28/22
|
Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations
|
pdf
|
|
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations
|
09/14/22
|
Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations
|
pdf
|
|
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
|
09/09/22
|
Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin
|
pdf
|
|
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations
|
09/08/22
|
Bausch Health Clarifies Release Provisions Related to its Exchange Offers and Consent Solicitations
|
pdf
|
|
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes
|
08/30/22
|
Bausch Health Announces Exchange Offers and Consent Solicitations for Certain Existing Senior Notes with Support from Approximately 23% of Outstanding Existing Senior Notes
|
pdf
|
|
Bausch Health Continuing Process Toward Separating Bausch + Lomb
|
08/22/22
|
Bausch Health Continuing Process Toward Separating Bausch + Lomb
|
pdf
|
|
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
|
08/10/22
|
Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit
|
PDF
|
|
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
|
08/10/22
|
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)
|
PDF
|
|
Bausch Health Announces Second-Quarter 2022 Results
|
08/09/22
|
Bausch Health Announces Second-Quarter 2022 Results
|
pdf
|
|
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
|
07/28/22
|
Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
|
PDF
|
|
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9
|
07/27/22
|
Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9
|
PDF
|
|
Salix Announces 2022 Gastrointestinal Health Scholars Program Winners
|
07/13/22
|
Salix Announces 2022 Gastrointestinal Health Scholars Program Winners
|
PDF
|
|
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors
|
06/23/22
|
Bausch Health Announces 2022 Annual Meeting of Shareholder Results, Updates to its Board of Directors
|
PDF
|
|
Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation
|
06/21/22
|
Bausch Health Issues Form 8-K for 2022 Annual Meeting of Shareholders Presentation
|
PDF
|
|
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022
|
06/20/22
|
Salix to Share New Data from XIFAXAN® (Rifaximin) Clinical Research at EASL's International Liver Congress™ 2022
|
PDF
|
|
Bausch Health Provides Update on Solta Medical
|
06/16/22
|
Bausch Health Provides Update on Solta Medical
|
PDF
|
|
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022
|
05/18/22
|
Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022
|
PDF
|
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
05/11/22
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
|
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions
|
05/10/22
|
Bausch Health And Bausch + Lomb Corporation Announce Closing Of Initial Public Offering Of Bausch + Lomb And Related Debt Transactions
|
PDF
|
|
Bausch Health Companies Inc. Announces First-Quarter 2022 Results
|
05/10/22
|
Bausch Health Companies Inc. Announces First-Quarter 2022 Results
|
pdf
|
|
Bausch Health Announces Thomas J. Appio As Chief Executive Officer
|
05/06/22
|
Bausch Health Announces Thomas J. Appio As Chief Executive Officer
|
PDF
|
|
Bausch + Lomb Corporation Announces Pricing of IPO
|
05/05/22
|
Bausch + Lomb Corporation Announces Pricing of IPO
|
pdf
|
|
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
|
05/03/22
|
Bausch + Lomb Presents Data from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
|
PDF
|
|
Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10
|
04/29/22
|
Bausch Health Companies Inc. Will Release First-Quarter 2022 Financial Results On May 10
|
PDF
|
|
Bausch + Lomb Corporation Announces Launch of IPO and Roadshow
|
04/28/22
|
Bausch + Lomb Corporation Announces Launch of IPO and Roadshow
|
pdf
|
|
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
|
04/28/22
|
Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation
|
pdf
|
|
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
|
04/28/22
|
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
|
PDF
|
|
Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference
|
04/27/22
|
Ortho Dermatologics Will Present Data at the 2022 Florida Society of Dermatology Physician Assistants New Wave Dermatology Conference
|
PDF
|
|
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
|
04/25/22
|
Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
|
pdf
|
|
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
|
04/21/22
|
Bausch + Lomb Reports More Than 48 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
|
pdf
|
|
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
|
04/20/22
|
Bausch + Lomb Corporation Seeking to Enter Into New Credit Facilities to Facilitate Previously Announced Separation from Bausch Health
|
PDF
|
|
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
|
04/18/22
|
Bausch + Lomb Will Present New Scientific Data During the American Society of Cataract and Refractive Surgery Annual Meeting
|
pdf
|
|
HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR
|
04/04/22
|
HALF OF IBS PATIENTS SURVEYED REPORT IBS SYMPTOMS MORE CHALLENGING TO MANAGE IN THE PAST YEAR
|
PDF
|
|
Bausch Health Will Reduce Debt By $200 Million
|
03/29/22
|
Bausch Health Will Reduce Debt By $200 Million
|
pdf
|
|
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
|
03/28/22
|
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
|
pdf
|
|
New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy
|
03/24/22
|
New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy
|
PDF
|
|
Gary Gemignani Will Join Solta Medical Corporation As Chief Financial Officer
|
03/22/22
|
Gary Gemignani Will Join Solta Medical Corporation As Chief Financial Officer
|
PDF
|
|
Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting
|
03/22/22
|
Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting
|
PDF
|
|
Bausch Health Announces Participation in Upcoming Investor Conferences
|
03/03/22
|
Bausch Health Announces Participation in Upcoming Investor Conferences
|
PDF
|
|
Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program
|
03/02/22
|
Ortho Dermatologics Now Accepting Applications for 2022 Aspire Higher Scholarship Program
|
PDF
|
|
Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings
|
03/01/22
|
Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings
|
PDF
|
|
Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference
|
02/24/22
|
Bausch Health Announces Participation At The J.P. Morgan Global High Yield & Leveraged Finance Conference
|
PDF
|
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance
|
02/23/22
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2021 Results And Provides 2022 Guidance
|
pdf
|
|
OraPharma Launches OraFit™ Custom Clear Dental Aligner System
|
02/22/22
|
OraPharma Launches OraFit™ Custom Clear Dental Aligner System
|
PDF
|
|
Salix Announces 2022 Gastrointestinal Health Scholars Program
|
02/15/22
|
Salix Announces 2022 Gastrointestinal Health Scholars Program
|
PDF
|
|
Solta Medical Corporation Files Registration Statement for Proposed Initial Public Offering
|
02/08/22
|
Solta Medical Corporation Files Registration Statement for Proposed Initial Public Offering
|
PDF
|
|
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2021 Financial Results on February 23
|
02/03/22
|
Bausch Health Companies Inc. Will Release Fourth-Quarter and Full-Year 2021 Financial Results on February 23
|
PDF
|
|
BAUSCH + LOMB AND PREVENT BLINDNESS LAUNCH ANNUAL AMD AWARENESS MONTH CAMPAIGN TO EDUCATE PATIENTS
|
02/01/22
|
BAUSCH + LOMB AND PREVENT BLINDNESS LAUNCH ANNUAL AMD AWARENESS MONTH CAMPAIGN TO EDUCATE PATIENTS
|
PDF
|
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
|
01/27/22
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
|
PDF
|
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes
|
01/27/22
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes
|
PDF
|
|
Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer
|
01/20/22
|
Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer
|
PDF
|
|
Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation
|
01/18/22
|
Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation
|
PDF
|
|
Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering
|
01/13/22
|
Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering
|
PDF
|
|
Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference
|
01/11/22
|
Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference
|
PDF
|
|
Bausch Health to Participate at the 40th Annual J.P. Morgan Healthcare Conference
|
01/05/22
|
Bausch Health to Participate at the 40th Annual J.P. Morgan Healthcare Conference
|
PDF
|
|
New Survey from Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patients
|
01/04/22
|
New Survey from Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patients
|
pdf
|
